目的 探討靈寶護(hù)心丹治療穩(wěn)定性冠心病的有效性和安全性。方法 選取 2022 年 10 月—2023 年 9 月在北京中醫(yī)藥大學(xué)第三附屬醫(yī)院心內(nèi)科門診就診的穩(wěn)定性冠心病患者 80 例，隨機(jī)分為對(duì)照組和試驗(yàn)組。對(duì)照組采用西醫(yī)常規(guī)治療，試驗(yàn)組在對(duì)照組的基礎(chǔ)上，給予靈寶護(hù)心丹每日 3 次、每次 4 粒治療。兩組患者均治療 4 周，比較兩組的心絞痛癥狀改善、硝酸甘油停減率、西雅圖量表評(píng)分、中醫(yī)證候積分及安全性指標(biāo)。結(jié)果 最終納入分析的患者共 77 例，其中試驗(yàn)組 39 例，對(duì)照組 38 例 ， 兩組患者基線資料具有可比性 。經(jīng) 4 周治療后， 試驗(yàn)組心絞痛總有效率（89.74%）顯著高于對(duì)照組（57.89%）（P＜0.01），試驗(yàn)組硝酸甘油總停減率（87.18%）顯著高于對(duì)照組（50.00%）（P＜0.01）。兩組患者治療后西雅圖量表和中醫(yī)證候評(píng)分均較治療前有顯著改善（P＜0.05），試驗(yàn)組西雅圖量表、中醫(yī)證候總積分改善程度優(yōu)于對(duì)照組 （P＜0.05），兩組安全性指標(biāo)無差異。結(jié)論 靈寶護(hù)心丹輔助西醫(yī)常規(guī)治療能夠有效地加強(qiáng)穩(wěn)定性冠心病的臨床療效，且具有安全性，值得臨床推廣。

Objective To explore the efficacy and safety of Lingbao Huxin Pill in the treatment of stable coronary artery disease. Methods A total of 80 patients who visited the Department of Cardiology Outpatient Clinic of Beijing University of Chinese Medicine Third Affiliated Hospital from October 2022 to September 2023 were randomly divided into control group and experimental group. The control group received conventional western medicine treatment, while the experimental group received Lingbao Huxin Pill in addition to the control group. Both groups were treated for four weeks, and the improvement of angina symptoms, nitroglycerin reduction rate, Seattle Scale score, traditional Chinese medicine (TCM) syndrome score, and safety indicators were compared between the two groups. Results A total of 77 patients were finally included in the analysis, including 39 patients in texperimental group and 38 patients in the control group. The baseline data of the two groups were similar and comparable. After four weeks of treatment, the effective rate of angina in experimental group was 89.74%, which was significantly higher than that in control group (57.89%) (P<0.01), and the nitroglycerin reduction rate in experimental group was 87.18%, which was significantly higher than that in control group (50.00%) (P<0.01). After treatment, both groups showed significant improvement in Seattle Scale and TCM syndrome scores compared with those before treatment (P<0.05), and the improvement of Seattle Scale and total TCM syndrome score in experimental group was better than that in control group (P<0.05). There was no difference in safety indicators between the two groups. Conclusion Lingbao Huxin Pill assisted with conventional western medicine treatment can effectively enhance the clinical efficacy of stable coronary artery disease, and is safe and worthy of clinical promotion.

R972

首都衛(wèi)生發(fā)展科研專項(xiàng)（2022-2-7035）